RBC Capital reiterates Intuitive Surgical stock rating on strong results By Investing.com

Intuitive Surgical reported Q1 2026 revenue of $2.77B and EPS of $2.50, beating expectations by about 6% and 19%, respectively, while sales rose 23% year over year and EPS increased 38%. Procedure volumes grew 16%-17% YoY, supported by strong dV5 utilization, though net placements were about 4% below expectations. RBC reiterated an Outperform rating and $650 target; other analysts remained constructive despite some target adjustments.

Analysis

The market is still underappreciating that ISRG is turning utilization into a compounding replacement cycle, not just a quarter of clean beats. Strong procedure growth plus high dV5 usage increases the installed-base “lock-in” effect: once surgeons and hospitals are routinized, replacement timing becomes less cyclical and more tied to throughput economics than to budget cycles. That creates a longer-duration earnings stream and gives ISRG more pricing power than the headline growth rate alone implies.

The near-term asymmetry is that expectations have moved faster than placements. If utilization stays elevated, the next leg is not from procedure growth alone but from a second-order acceleration in system demand, service mix, and instrument pull-through over the next 2-4 quarters. The risk is that a modest placement miss today becomes a bigger multiple problem if management sounds cautious on conversion of utilization into orders, because the stock is pricing a very high-quality compounding story and not a mid-teens hardware cycle.

The consensus may be over-fixated on valuation and underweight the operating leverage embedded in the model. Gross margin at this level means incremental procedure growth can translate into disproportionate EPS upside even if placements are lumpy; that makes the business more resilient than most medtech peers in a slower macro tape. The main contrarian issue is not fundamentals, but duration: if rates stay high and growth styles de-rate, the stock can stall even while the business keeps compounding, creating a better entry on volatility than on momentum chase.

For competitors, the pressure is indirect but real: hospitals allocating capital to one platform with rising utilization can delay consideration of alternative minimally invasive systems, while suppliers tied to lower-end surgical equipment may see share pressure as the premium platform widens its moat. The bigger second-order effect is on aftermarket economics across the ecosystem, where higher installed utilization tends to pull more disposable/instrument demand and reinforce switching costs over a multi-year horizon.

Key Decisions for Investors

• Stay long ISRG on pullbacks, but avoid chasing strength after a gap up; better entry is on any 3-5% retracement over the next 1-2 weeks, with a 6-12 month view.
• Use a call spread in ISRG (e.g., 3-6 month upside call spread) to express continued multiple expansion while limiting exposure to valuation compression; best if you expect another utilization-led re-rating.
• Relative value: long ISRG / short a lower-quality medtech peer basket over 3-6 months, targeting outperformance if capital spending rotates toward platforms with visible installed-base monetization.
• If you already own ISRG, consider trimming only if management guidance fails to convert utilization into placement upside next quarter; that is the key catalyst-risk checkpoint.
• Buy on volatility if rates spike and growth names de-rate: ISRG’s business quality supports a better risk/reward on market-wide drawdowns than on euphoric momentum days.